Chemokine begins second study of CTCE-0214 to increase white blood cell count

By Angela McDaniels

Seattle, Dec. 15 - Chemokine Therapeutics Corp. said it has begun a phase 1b study to evaluate the safety, pharmacodynamics and pharmacokinetic profile of CTCE-0214, the company's lead dug candidate, as a single injection, multi-dose therapy and in combination with granulocyte colony stimulating factor.

CTCE-0214 is designed to trigger trafficking of immune system cells and stem cells and regenerate white blood cells and platelets, the company said.

The company has begun dosing the first cohort of subjects in the first of a three-stage protocol, undertaken in Tacoma, Wash., that will include at least 50 healthy adult volunteers.

The first stage of the clinical study involves a single dose-escalation design followed in stage two by repeat administration up to three doses. The final stage is designed to explore the possible use of CTCE-0214 in conjunction with G-CSF.

The company expects to announce preliminary results of the trial in the second half of 2006.

A phase 1a trial of CTCE-0214 demonstrated that it is associated with significant increases in total white blood cell and neutrophil in subjects in the highest dose cohort, with an increase of over 300% more neutrophils on treatment then on placebo, the company said.

Chemokine Therapeutics is a biotechnology company based in Vancouver, B.C., that develops drugs using stem cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.